Biomax Genetics

biomaxgenetics.com

Biomax Genetics is a leader in the field of DNA extractions in South Africa. Offering standard or custom DNA/RNA extraction kits and services, our range of genomics services includes high quality DNA extractions from plant and animal tissues, as well as high molecular weight extractions.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MedTech, Industrial Impact

MAXCYTE LICENCES WITH CATAMARAN BIO TO ADVANCE ITS CAR-NK CELL THERAPY PROGRAMS

MaxCyte | January 04, 2023

news image

MaxCyte, a leading commercial cell-engineering company, announced the signing of a strategic platform license (SPL) with Catamaran Bio, a biotechnology enterprise creating off-the-shelf chimeric antigen receptor (CAR)-NK cell therapeutics to cure a wide range of cancers. While Catamaran acquires non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform per the terms of the agreement, in exchange, MaxCyte will ...

Read More

Medical

PHARMACTIVE ENTERS STRATEGIC PARTNERSHIP WITH NUTRACONNECT FOR APAC

Pharmactive | June 08, 2022

news image

Pharmactive Biotech Products, S.L.U., announces a new strategic partnership with Singapore-based Nutraconnect Pte, Ltd. to bring innovative, scientifically backed nutraceutical ingredients to the Asia-Pacific marketplace (not including Australia and New Zealand). The partnership will combine the strengths of both companies into a greater whole. Pharmactive will provide its well-supported, clean-label botanical extract ingredients, while Nutraconnect will function as a growth engin...

Read More

MedTech

ENVERIC BIOSCIENCES ANNOUNCES REVERSE STOCK SPLIT

Enveric Biosciences | July 15, 2022

news image

Enveric Biosciences, Inc. a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 50 pre-split shares. The reverse stock split will become effective at 4:05 p.m., New York time, on Thursday, July 14, 2022. Enveric’s common stock will continue to be traded on the Nasdaq Capital Market under the symbol “E...

Read More

Medical

SESEN BIO PARTNERS WITH HIKMA PHARMACEUTICALS FOR THE REGISTRATION AND COMMERCIALIZATION OF VICINEUM

Sesen Bio | December 02, 2020

news image

Sesen Bio, a late-stage clinical organization creating focused on combination protein therapeutics for the therapy of patients with cancer, and Hikma Pharmaceuticals, a worldwide pharmaceutical organization and driving permitting partner in the Middle East and North Africa ("MENA") area spend significant time in the turn of events and commercialization of an expansive scope of great medicines, today declared that the organizations have gone into exclusive licensing agreement for the re...

Read More
news image

MedTech, Industrial Impact

MAXCYTE LICENCES WITH CATAMARAN BIO TO ADVANCE ITS CAR-NK CELL THERAPY PROGRAMS

MaxCyte | January 04, 2023

MaxCyte, a leading commercial cell-engineering company, announced the signing of a strategic platform license (SPL) with Catamaran Bio, a biotechnology enterprise creating off-the-shelf chimeric antigen receptor (CAR)-NK cell therapeutics to cure a wide range of cancers. While Catamaran acquires non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform per the terms of the agreement, in exchange, MaxCyte will ...

Read More
news image

Medical

PHARMACTIVE ENTERS STRATEGIC PARTNERSHIP WITH NUTRACONNECT FOR APAC

Pharmactive | June 08, 2022

Pharmactive Biotech Products, S.L.U., announces a new strategic partnership with Singapore-based Nutraconnect Pte, Ltd. to bring innovative, scientifically backed nutraceutical ingredients to the Asia-Pacific marketplace (not including Australia and New Zealand). The partnership will combine the strengths of both companies into a greater whole. Pharmactive will provide its well-supported, clean-label botanical extract ingredients, while Nutraconnect will function as a growth engin...

Read More
news image

MedTech

ENVERIC BIOSCIENCES ANNOUNCES REVERSE STOCK SPLIT

Enveric Biosciences | July 15, 2022

Enveric Biosciences, Inc. a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 50 pre-split shares. The reverse stock split will become effective at 4:05 p.m., New York time, on Thursday, July 14, 2022. Enveric’s common stock will continue to be traded on the Nasdaq Capital Market under the symbol “E...

Read More
news image

Medical

SESEN BIO PARTNERS WITH HIKMA PHARMACEUTICALS FOR THE REGISTRATION AND COMMERCIALIZATION OF VICINEUM

Sesen Bio | December 02, 2020

Sesen Bio, a late-stage clinical organization creating focused on combination protein therapeutics for the therapy of patients with cancer, and Hikma Pharmaceuticals, a worldwide pharmaceutical organization and driving permitting partner in the Middle East and North Africa ("MENA") area spend significant time in the turn of events and commercialization of an expansive scope of great medicines, today declared that the organizations have gone into exclusive licensing agreement for the re...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us